NASDAQ:PLXP

PLx Pharma (PLXP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,000 shs
Average Volume
12.96 million shs
Market Capitalization
$603,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PLXP stock logo

About PLx Pharma Stock (NASDAQ:PLXP)

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

PLXP Stock News Headlines

Protalix Biotherapeutics Inc (PLX)
Vertex Pharmaceuticals Inc VRTX
Perma Bull: This is what terrifies me about AI
For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.
Vietnam National Petroleum Group (PLX)
PLx Pharma Inc (PLXPQ)
PLXPQ PLx Pharma Inc.
Perma Bull: This is what terrifies me about AI
For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.
PLx Pharma Inc. Receives Nasdaq Delisting Notice
Short Volatility Alert: Plx Pharma Inc
PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma down after Q3 revenue fell 94% Y/Y
Earnings Preview: PLx Pharma
PLXP Aug 2022 5.000 call
PLx Pharma downgraded at Oppenheimer after Q2 miss
PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%
See More Headlines
Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
2002

Profitability

Net Income
$-46,130,000.00
Net Margins
-606.91%
Pretax Margin
-606.91%

Debt

Sales & Book Value

Annual Sales
$4.54 million
Book Value
$1.30 per share

Miscellaneous

Free Float
26,530,000
Market Cap
$603,000.00
Optionable
Not Optionable
Beta
3.79

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Natasha Giordano
    President, Chief Executive Officer & Director
  • Rita M. O'Connor
    CFO, Head-Manufacturing & Supply Chain
  • Mayme Lou Roettig
    Executive Medical Director
  • Thomas L. Long
    VP-Manufacturing & Technical Operations
  • Lawrence R. Perkins
    Chief Restructuring Officer

PLXP Stock Analysis - Frequently Asked Questions

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. The biotechnology company had revenue of $6.60 million for the quarter, compared to the consensus estimate of $4.10 million. PLx Pharma had a negative net margin of 606.91% and a negative trailing twelve-month return on equity of 291.11%. The business's quarterly revenue was up 560.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.40) earnings per share.

What other stocks do shareholders of PLx Pharma own?
When did PLx Pharma IPO?

PLx Pharma (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

This page (NASDAQ:PLXP) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners